%0 Journal Article
%T Rythym
%A GaBI Journal Editor
%J Generics and Biosimilars Initiative Journal
%D 2012
%I Pro Pharma Communications International
%X Clinical biosimilar data should be accessible to allFDA Form 483: punishment or learning opportunity?Biosimilars: challenges getting into the USBiosimilar regulatory issuesNew Amgen ¡®182¡¯ Enbrel patentInterchangeability or substitution of biosimilarsIs anyone developing biosimilars of darbepoetin alfa in Europe?Biosimilar patents expiring before 2020
%U http://gabi-journal.net/rhythm.html